The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial

By Yu Zhaocai  

Supportive Care in Cancer, Vol. 17, Iss. 1, 2009-01 ,pp. : 99-102

Springer Publishing Company

Access to resources Recommend Favorite

Phase II Trial of Topotecan, Carboplatin, and Paclitaxel as Front-Line Therapy in Suboptimal Advanced Epithelial Ovarian Cancer

By Bolis G.   Scarfone G.   Villa A.   Parazzini F.  

Gynecologic Oncology, Vol. 81, Iss. 2, 2001-05 ,pp. : 331-333

Elsevier

Access to resources Recommend Favorite

Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin

By Choi Chel   Kim Min   Park Jin-Young   Yoon Aera   Kim Ha-Jeong   Lee Yoo-Young   Kim Tae-Joong   Lee Jeong-Won   Kim Byoung-Gie   Bae Duk-Soo  

Supportive Care in Cancer, Vol. 22, Iss. 5, 2014-05 ,pp. : 1181-1187

Springer Publishing Company

Access to resources Recommend Favorite

Phase I Study of Alternating Doublets of Topotecan/Carboplatin and Paclitaxel/Carboplatin in Patients with Newly Diagnosed, Advanced Ovarian Cancer

By Gordon A.N.   Hancock K.C.   Matthews C.M.   Messing M.   Stringer C.A.   Doherty M.G.   Teneriello M.  

Gynecologic Oncology, Vol. 85, Iss. 1, 2002-04 ,pp. : 129-135

Elsevier

Access to resources Recommend Favorite

Phase I Trial of Carboplatin, Paclitaxel, Etoposide, and Cyclophosphamide with Granulocyte Colony Stimulating Factor as First-Line Therapy for Patients with Advanced Epithelial Ovarian Cancer

By Tung N.   Berkowitz R.   Matulonis U.   Quartulli M.   Seiden M.   Kim Y.   Niloff J.   Cannistra S.A.  

Gynecologic Oncology, Vol. 77, Iss. 2, 2000-05 ,pp. : 271-277

Elsevier

Access to resources Recommend Favorite